COMPANY

Lisata Therapeutics

HQ: Liberty Corner, NJ source · lisata.com ↗ · Mid-Atlantic

Keywords: oncology cancer solid tumors Coronary Microvascular Dysfunction Pancreatic Ductal Adenocarcinoma Myocardial Ischemia Cholangiocarcinoma Gallbladder Cancer Gallbladder Carcinoma Intrahepatic Cholangiocarcinoma Extrahepatic Cholangiocarcinoma Bile Duct Cancer Gall Bladder Cancer Gall Bladder Carcinoma Coronary Microvascular Disease Microvascular Coronary Artery Disease Pancreas Cancer Pancreatic Carcinoma Pancreas Adenocarcinoma Unresectable Pancreatic Cancer Metastatic Pancreatic Cancer PDAC - Pancreatic Ductal Adenocarcinoma Critical Limb Ischemia Buerger Disease Thromboangiitis Obliterans Atherosclerosis Obliterans Chronic Kidney Diseases Covid-19 Pancreatic Cancer Kidney Cancer Diabetes Mellitus Brain and Central Nervous System Tumors Stage IV Melanoma Stage III Melanoma Chronic Myocardial Ischemia Refractory Angina Pectoris Advanced Coronary Heart Disease Melanoma (Skin) CLBS16 CLBS12 CLBS201

Location: Liberty Corner, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

$225.0MRaised (2 yrs)17Trials (company is sponsor)

Timeline

2030-01 Trial start 1: Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC source ↗
Sep 17, 2026 Raise Private placement: $225M (total, as published), announced Sep 17, 2026. Source: SEC filing. source ↗
May 13, 2023 Trial start Phase 2: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors source ↗
Jan 10, 2022 Trial start Phase 1: CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM) source ↗
Oct 29, 2020 Trial start Phase 2: A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction source ↗
Oct 5, 2020 Trial start Phase 1: CLBS119 for Repair of COVID-19 Induced Pulmonary Damage source ↗
Jul 31, 2018 Trial start Phase 1: CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer source ↗
Apr 19, 2018 Trial start Phase 2: Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease source ↗
Nov 1, 2017 Trial start Phase 2: Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) source ↗
2016-02 Trial start Phase 2: Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study) source ↗
2014-10 Trial start Phase 3: Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma source ↗
2012-04 Trial start Phase 3: Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina source ↗
2011-12 Trial start Phase 2: NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction source ↗
2008-11 Trial start Phase 2: Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery source ↗
2007-10 Trial start —: ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study) source ↗
2006-04 Trial start Phase 2: ACT34-CMI -- Adult Autologous CD34+ Cells source ↗
2001-11 Trial start Phase 1: Vaccine Therapy in Treating Patients With Kidney Cancer source ↗
2000-07 Trial start Phase 1/Phase 2: Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma source ↗

Funding

Raised: $225.0M. Last 2 years.

Sep 17, 2026 Private placement: $225M (total, as published), announced Sep 17, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 17

Record	Title	Phase	Status	Start	Primary completion
NCT05712356	A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors	Phase 2	Completed	May 13, 2023	Apr 5, 2026 (actual)
NCT04614467	A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction	Phase 2	Terminated	Oct 29, 2020	Sep 28, 2022 (actual)
NCT06592664	Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC	1	Withdrawn	2030-01	2035-01 (estimated)
NCT02501018	Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)	Phase 2	Completed	Nov 1, 2017	May 19, 2022 (actual)
NCT04990427	CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)	Phase 1	Completed	Jan 10, 2022	Jan 26, 2023 (actual)
NCT04522817	CLBS119 for Repair of COVID-19 Induced Pulmonary Damage	Phase 1	Withdrawn	Oct 5, 2020	2021-05 (estimated)
NCT03517176	CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer	Phase 1	Completed	Jul 31, 2018	Jun 19, 2020 (actual)
NCT00014131	Vaccine Therapy in Treating Patients With Kidney Cancer	Phase 1	Terminated	2001-11	2009-12 (actual)
NCT00300053	ACT34-CMI -- Adult Autologous CD34+ Cells	Phase 2	Completed	2006-04	2008-03 (actual)
NCT03508609	Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease	Phase 2	Completed	Apr 19, 2018	Dec 10, 2019 (actual)
NCT02691247	Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)	Phase 2	Completed	2016-02	2019-03 (actual)
NCT00814593	Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery	Phase 2	Withdrawn	2008-11	2011-04 (actual)
NCT01875653	Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma	Phase 3	Terminated	2014-10	2016-01 (actual)
NCT01508910	Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina	Phase 3	Completed	2012-04	2015-11 (actual)
NCT00545610	ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)	Not listed	Completed	2007-10	2010-04 (actual)
NCT01495364	NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction	Phase 2	Completed	2011-12	2014-06 (actual)
NCT00012064	Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma	Phase 1/Phase 2	Completed	2000-07	2011-04 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-10-02 Raise Private raise (SEC Form D): $351.9M sold; issuer “LISATA THERAPEUTICS, INC.”. Verified from the SEC filing. SEC filing ↗